Stay updated on Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial

Sign up to get notified when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The footer’s site revision label changes from v3.7.1 to v3.7.2; the page remains a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T19:47:32.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.0 to v3.7.1; the page otherwise continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T20:20:06.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    32 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error screen, replacing the study content; accompanying additions include basic navigation text (Home, Revision: v3.7.0) while a large portion of study-related content appears to have been removed.
    Difference
    20%
    Check dated 2026-09-19T19:16:22.000Z thumbnail image
  5. Check
    53 days ago
    Change Detected
    Summary
    Revision: v3.6.6 is now shown instead of v3.6.5, indicating a new page build. This update does not alter the study details or how users interact with the page.
    Difference
    0.1%
    Check dated 2026-08-29T18:59:45.000Z thumbnail image
  6. Check
    74 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.6.5 in the study documents section. This indicates an updated document version has been posted or referenced.
    Difference
    0.1%
    Check dated 2026-08-08T18:02:12.000Z thumbnail image
  7. Check
    88 days ago
    Change Detected
    Summary
    The page's revision tag was updated from v3.6.3 to v3.6.4. This indicates a small platform or content update rather than a change to study details.
    Difference
    0.1%
    Check dated 2026-07-25T10:29:59.000Z thumbnail image

Stay in the know with updates to Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.